key: cord-0747116-gakll5cz authors: Bruzzone, Chiara; Bizkarguenaga, Maider; Gil-Redondo, Rubén; Diercks, Tammo; Arana, Eunate; García de Vicuña, Aitor; Seco, Marisa; Bosch, Alexandre; Palazón, Asís; San Juan, Itxaso; Laín, Ana; Gil-Martínez, Jon; Bernardo-Seisdedos, Ganeko; Fernández-Ramos, David; Lopitz-Otsoa, Fernando; Embade, Nieves; Lu, Shelly; Mato, José M.; Millet, Oscar title: SARS-CoV-2 infection dysregulates the metabolomic and lipidomic profiles of serum date: 2020-10-05 journal: iScience DOI: 10.1016/j.isci.2020.101645 sha: 2aec593e559d8ac574b8e022db7d9b4b767036e9 doc_id: 747116 cord_uid: gakll5cz COVID-19 is a systemic infection that exerts significant impact on the metabolism. Yet, there is little information on how SARS-CoV-2 affects metabolism. Using NMR spectroscopy, we measured the metabolomic and lipidomic serum profile from 263 (training cohort) + 135 (validation cohort) symptomatic patients hospitalized after positive PCR testing for SARS-CoV-2 infection. We also established the profiles of 280 persons collected before the coronavirus pandemic started. PCA analyses discriminated both cohorts, highlighting the impact that the infection has in overall metabolism. The lipidomic analysis unraveled a pathogenic redistribution of the lipoprotein particle size and composition to increase the atherosclerotic risk. In turn, metabolomic analysis reveals abnormally high levels of ketone bodies (acetoacetic acid, 3-hydroxybutyric acid and acetone) and 2-hydroxybutyric acid, a readout of hepatic glutathione synthesis and marker of oxidative stress. Our results are consistent with a model in which SARS-CoV-2 infection induces liver damage associated with dyslipidemia and oxidative stress. SARS-CoV-2 is a highly transmissible virus described for the first time in Wuhan (Hubei Province, China) in December of 2019 (Zhu et al., 2020 . Yet, there are evidences showing that SARS-CoV-2 emerged in Europe earlier than thought, after the analysis of wastewater samples collected in Italy by December 2019 (La Rosa et al., 2020) The virus shares sequence identity with other related coronaviruses such as SARS-CoV and MERS-CoV (Zhou et al., 2020b) . Upon viral infection, an incubation period ranging from 1 to 14 days (Lauer et al., 2020) results in the onset of COVID-19 disease (Munster et al., 2020) . Unfortunately, this mechanism is very efficient and SARS-CoV-2 has rapidly spread worldwide, resulting in the ongoing coronavirus pandemic. According to the WHO, more than 26 million cases have been reported worldwide, having thus far resulted in about 864.000 deaths so far (WHO, 2020). There is a plethora of symptoms associated to COVID-19 including fever, nonproductive cough, tiredness, sore throat, nasal congestion, diarrhoea, conjunctivitis, headache, dyspnea, nausea/vomiting and in some cases loss of taste, smell or skin J o u r n a l P r e -p r o o f problems (Song et al., 2020; Tammaro et al., 2020; Wei et al., 2020) . In many cases the prognosis is favourable, but approximately 20% of COVID-19 patients require intensive care unit admission due to severe acute respiratory syndrome, that may be accompanied by multiorgan failure (Richardson et al., 2020) . Such patients also may develop neurological problems (Niazkar et al., 2020) , haematological abnormalities (Liu et al., 2020) , and suffer venous thromboembolism (Al-Ani et al., 2020) . The mortality rate is very high (ca. 17%) amongst elderly or people with chronic diseases (Zhou et al., 2020a) . The disease aetiology is progressively being unravelled, but the underlying molecular mechanisms and the associated metabolic alterations remain much more poorly understood. To the best of our knowledge, there are only three public studies that analyzed the metabolism of patients with COVID-19 (Shen et al., 2020; Thomas et al., 2020; Wu et al., 2020) . The observed molecular changes in the sera of COVID-19 patients implied significant metabolic suppression as well as a dysregulation of the macrophage function, platelet degranulation and the complement system pathway among others. These results are in line with the mechanism observed for other viral infections like Ebola (Kyle et al., 2019) and highlight the systemic characteristic of the disease that may affect further organs such as the liver. Yet, these conclusions were mostly obtained from proteomics data and would demand complementary metabolomic analyses of much larger cohorts. The aim of this study was to investigate whether there is a specific metabolic and/or lipoprotein profile associated with patients diagnosed with COVID-19 by a positive RT-PCR testing and showing clear manifestations of the disease. To that end, we have used NMR-based metabolomics that is particularly well suited for the characterization of complex solutions like serum and is capable at the same time to quantify and identify both, known and unknown metabolites. MS is also widely used for metabolomics studies, because its extreme sensitivity and ability to analyze a massive number of metabolites using very small sample amounts. That said, NMR is fully quantitative and can also classify and quantify lipoproteins in a robust and reliable way, with higher resolution than ultracentrifugation (Chapman et al., 1981) . We have analysed a cohort with 263 COVID-19 positive serum samples obtained from patients To investigate the metabolic and lipidomic changes induced by SARS-CoV-2 infection, we analysed a cohort of 263 COVID-19 patients by NMR spectroscopy (COVID). These individuals presented compatible symptomatology that was confirmed by PCR-testing upon admission to the hospital. A subset of 43 samples from the COVID cohort was tested for antibodies, where 21 (48%) gave positive for IgG only and 11 (26%) for IgG and IgM. This sub-cohort well represents the COVID cohort in terms of gender and age. Hence, this set of hospitalized represents well the acute and severe symptomatic phase of the disease. As a control, we employed a cohort of sera from 280 individuals of the working population from the same geographical region, but collected in pre-COVID times (2018-2019) during a routine medical check-up and with no other exclusion criteria than having suffered a serious illness like cancer or stroke within the 3 months preceding the sample collection (preCOVID). The NMR Carr-Purcell-Meiboom-Gill (CPMG) spectrum (Embade et al., 2016) filters out the lipoprotein fraction, rendering the metabolic profiling of the serum. Already a visual inspection of such spectra revealed substantial differences, a notion that was further substantiated by an unsupervised PCA analysis of the 40 metabolites that can be routinely quantified from this type of spectrum (Figure 2A,B) . In turn, a regular 1 H NMR spectrum of serum also reveals the complex lipoprotein profile (Jiménez et al., 2018) , as shown in Figure 1 for representative examples of the COVID and preCOVID cohorts, where 21 main lipoprotein fractions, 74 lipoprotein subfractions and another important serum parameters can nowadays be identified and quantified by spectra deconvolution. Such set includes lipoproteins and their respective subfractions (Table S5 ). The NMR spectrum also allows a detailed characterization of the different J o u r n a l P r e -p r o o f lipoprotein subclasses, with the quantification of the total and free cholesterol, phospholipids, triglycerides, Apo-A1, Apo-A2 and Apo-B. PCA analysis shows a reasonable separation between COVID and preCOVID cohorts ( Figure 2C ,D), suggesting that SARS-CoV-2 infection may also inflict changes in the blood lipoprotein composition. These differences observed by unsupervised analysis were also confirmed by Orthogonal Partial Least-Squares Discriminant Analysis (OPLS-DA) for the full set of serum metabolites and lipoprotein subclasses ( Figure 2E ), using 1 predictive and 1 orthogonal components. Not surprisingly, OPLS-DA analysis showed a high degree of separation between groups, also with very good predictability (AUROC validation = 0.977) (Table 1) and statistical significance (p-value < 0.01) ( Figures S4-S5) . Remarkably, even when metabolites and all the different lipid fractions were included as independent classes in an OPLS-DA analysis, a reasonable degree of clustering was achieved ( Figure 2F ). Since COVID-19 severity increases particularly for elderly people, a potential caveat is the substantial age difference between the COVID and the preCOVID cohorts. Yet, two sub-cohorts of 112 samples each, properly balanced for gender and age distribution, Table S4 ). These results rule out a bias due to improper randomization of the control group. Another concern is that, during the peak of the pandemia, collecting protocols could not be completely abided, what could affect the results. However, the analysis of a second patient cohort from a different hospital yielded the same results ( Figure S2 ), which strongly suggest that technical handling aspects may not decisively affect the outcome. Remarkably, the added cohort includes almost 400 patient samples which, to our knowledge is the largest metabolomic analysis reported in COVID-19. The pre-COVID cohort belongs to a collection of samples from healthy population that were collected in a period of two years prior to COVID-19 outbreak. To evaluate the effect of storage of the samples, we performed a PCA analysis of a subset of the first samples collected (in 2016), compared to the last samples to be frozen (in 2018). As shown in Figure S3 , the two groups cannot be separated, indicating that the freezing period does not significantly biases the cohort. It is instructive to analyze the changes observed upon SARS-CoV-2 infection in more depth since it is already known that SARS-CoV-2, SARS-CoV-1 or MERS-CoV infection may affect the liver (Kukla et al., 2020), eventually inducing long-term injury in some patients (Wu et al., 2017) . The effect of SARS-CoV-2 infection on the different lipoprotein classes and subclasses, as analyzed by 1 H NMR, is summarized in Figures 2D, 3 and Table S1 . Our findings are consistent with a TG-rich lipoprotein profile in the were significantly increased in COVID-19 patients. Amongst these, the largest increase (by factor 2) was observed for TG-LDL ( Figure 3 ). Inversely, the total cholesterol (TC) and mean concentration of bound TC-LDL and TC-HDL (both are the main carriers of cholesterol) was decreased in COVID-19 serum, most prominently for TC-HDL subfractions 4 and 3. In contrast, TC-VLDL and TC-IDL levels were slightly, but significantly increased. The concentrations of cholesteryl esters and phospholipids in the main lipoprotein classes showed a profile similar to that observed for TG and TC. All these observations suggest a remodeling of the lipoprotein particle phenotype in COVID-19 patients, with a reduction of the mean HDL size, an enlargement of the mean size of LDL and increased level of VLDL subclasses with intermediate size. Among the apolipoproteins, both Apo-A1 and Apo-A2, the major apoprotein components of HDL, markedly decreased in COVID-19 patient serum, although they maintained a normal Apo-A1 to Apo-A2 ratio, indicating that SARS-CoV-2 infection did not altered HDL composition. The Apo-B to Apo-A1 ratio, a balance between atherogenic and anti-atherogenic particles, markedly increased by about 2-fold indicating an increased cardiovascular risk for COVID-19 patients. Our analysis of low molecular mass metabolites NMR showed that ketone bodies (acetoacetic acid, 3-hydroxybutyric acid, and acetone) were markedly elevated in the J o u r n a l P r e -p r o o f serum of COVID-19 patients. Acetoacetic acid increased from 1.14E-02 to 5.54E-02 mmol/L (p <0.0001, 385%), 3-hydroxybutyric acid from 6.6E-02 to 2.7E-01 mmol/L (p <0.0001, 302%), and acetone from 2.75E-02 to 6.45E-02 mmol/L (p <0.0001, 134%) compatible symptomatology and 100% of them confirmed by RT-PCR testing. From the antibody test, 75% of the patients also already developed IgG antibodies and about a third of them also IgM antibodies. Importantly, these patients did not necessarily have previous health problems as the only inclusion criterion was the SARS-CoV-2 infection. Taken together, this patient cohort is, on average, representing the acute symptomatic phase of the disease, approximately between 14 and 21 days from onset. As a control cohort, we have used a pool of samples of similar size (n=280), that belongs to healthy population and acquired before the advent of COVID-19. Although the two cohorts have different average age, we have demonstrated that this is not a contributing factor to the observed differences ( Figure S1 ). One of the most striking differences arise from the lipoprotein distribution. Endogenous lipoproteins are classified according to lipid and apolipoprotein composition in VLDL, IDL, LDL and HDL (Feingold KR, 2018) . HDL are classified as atheroprotective because they are involved in transport of cholesterol to the liver. Upon an excess of fatty acids and TC in the liver, these lipids are converted into TG and cholesteryl esters respectively, wrapped with apolipoproteins (mainly Apo-B), decorated with phospholipids and placed into circulation as VLDL where, via capillaries, they get in contact with the various tissues. Our NMR analysis clearly reflects a scenario with a severe lipoprotein dysregulation towards increased TG and abnormal lipoprotein particle distribution, with an increase of VLDL subclasses with intermediate size. These results are in line with other observations using MS (Shen et al., 2020; Thomas et al., 2020) , but our study, on a very large cohort, adds granularity to the lipoprotein distribution and allows devising a detailed landscape of lipoprotein rearrangement upon SARS-CoV-2 infection. This acute dysregulation is obviously pathogenic and, when found in non-acute episodes such as metabolic syndrome or NAFLD, it would fit well with increased atherosclerotic risk. The metabolic profile of COVID-19 patients, also obtained by NMR spectroscopy, agrees well with the lipidomic analysis. The excess of ketone bodies (acetone, acetoacetic acid and 3-hydroxybutyric acid) suggests that they are being used as an alternative energy source due to a sort of diabetic ketoacidosis. Consistently, glucose levels are also elevated but this has to be taken with extreme caution since samples were not collected at fasting conditions. Some other metabolites such as succinate and pyruvate among others are consistent with impaired central metabolism and/or mitochondrial dysfunction. We have recently observed that thrombocytopenia in COVID-19 patients (Connors and Levy, 2020) ultimately results in elevated porphyrin levels, in a similar way as observed in porphyria, a family of diseases that always imply oxidative stress, mitochondrial impairment and liver damage. The cohort is limited to the same world region, which may partially compromise the generality of the conclusions due to geographical biases. Freezing the samples may alter the metabolite concentrations even though the two control groups ( Figure S3) suggest that this problem does not significantly affect the conclusions of the present study. Samples which were collected prior to the pandemics (preCOVID) may have not used the same protocol than for the COVID cohorts. All the samples correspond to the acute phase of the disease and the study would benefit from the study of samples from patient's at different stages of the SARS-CoV-2 infection. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Oscar Millet (omillet@cicbiogune.es). This study did not generate new unique reagents All parameter values, datasets, and used in the model are included in the Supplemental The authors declare no competing interests. The Table has Table S5 . Raw spectroscopical data, Related to Transparent Methods and Figures 1-4 . The Table has All serum samples were provided by the Basque Biobank for research (BIOEF). According to the Declaration of Helsinki principles, all participants in the study provided informed consent to clinical investigations, with evaluation and approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016). All data was anonymized to protect the confidentiality of participants. The patient cohort (COVID; n = 263) presented different symptoms compatible with COVID-19, and had been diagnosed as SARS-CoV-2 positive on nasal swab samples by a RT-PCR assay targeting viral RNA regions encoding the envelope protein E and RNA-dependent RNA polymerase (RNase P). RNA was extracted from samples with the MagNa Pure 96 system (Roche, Penzberg, Germany). As regard the Real-time reverse-transcription PCR a 25 μL reaction contained 5 μL of RNA, 12.5 μL of 2 x reaction buffer provided with Superscript III one step RT-PCR system with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany; containing 0.4 mM of a 50 mM magnesium sulphate solution (Invitrogen), and 1 μg of nonacetylated bovine serum albumin (Roche). All oligonucleotides were synthesised and provided by Tib-Molbiol (Berlin, Germany). Thermal cycling was performed at 55°C for 10 min for reverse transcription, followed by 95°C for 15 s, 58°C for 30 s using the Applied Biosystems ViiA7 instrument (Applied Biosystems, Hong Kong, China). The patients were in the hospital urgency room at the moment of sample collection and all were hospitalized after that, so the hospital diet is not a confounding parameter. The serum samples of the control cohort (preCOVID; n = 280) were collected in 2018/2019 in overnight fasting conditions, well before start of the current COVID pandemia, by Osarten Kooperatiba Elkartea (Mondragon Cooperative) as extra aliquots during the routine annual medical tests of their employees in the Basque Country by OSARTEN. Further patient data was also registered, including serum biochemical parameters (Tables S2 and S3 ) and life style habits (data not shown). Both cohorts were collected within the same geographical region (Basque Country) and handled by the same biobank (Basque Biobank). The procedures, mainly temperature, clotting tube and clotting time, were in principle the same. However, since the patient cohort were collected during the peak of the pandemia, it cannot be assured that all these protocols could be completely abided by the clinicians. For this reason, a second patient cohort (135 additional samples), coming from a second hospital, was analyzed. Since the two hospitals are totally autonomous, the two cohorts represent a perfect set to investigate the variability in terms of sample handling. Samples were stored at -80 °C until measured. The delivered frozen serum sample (500 L) were individually left to thaw at room temperature during several minutes. NMR samples were then prepared by a SamplePro Tube (Bruker Biospin) robot system for liquid handling with integrated temperature control. Briefly, every sample was automatically mixed with phosphate buffer (containing trimethylsilylpropionic acid-d 4 sodium salt, TSP 0.1 mM, and 10% D2O) at a 1:1 (v/v) ratio and 600 µL were then filled into a 5 mm NMR tube. After manually shaking every sample for several seconds, the NMR tubes were stored at 5 °C inside a tempered SampleJet automatic sample changer mounted on a 600 MHz IVDr spectrometer (Bruker Biospin, Germany). RBD (aa 319-541) was codon-optimized for expression in human cells. The construct was synthesized by GenScript and subcloned into the pHLsec vector (addgene) at cloning site AgeI and KpnI. In order to enhance the affinity purification, a His6× tag was added at the C terminus of the construct. HEK293F suspension cells (Thermo Fisher Scientific) were transiently transfected and split into 200 ml culture flasks at 0.7 × 10 6 cells per ml. DNA was filtered and mixed (1:1) with transfection reagent FectoPRO (Polyplus Transfections) for 10 min at RT and added to the cells. After incubation at 37 °C, 180 rpm, 8% CO2 in a Minitron Pro shaker (Infors HT) for 7 days, cell cultures were harvested by centrifugation at 4000×g for 30 min, and supernatants were collected and filtered with a 0.22 µm System filter (Corning). Supernatants were passed through a HisTrap Ni-NTA column (GE Healthcare) at 4 ml min−1. Washing was performed with a 10-column volume of 20 mM Tris pH 9.5, 200 mM NaCl, and 4% of elution Buffer (20 mM Tris pH 9.5, 200 mM NaCl, 500 mM imidazole). Fractions containing RBD were eluted, collected, concentrated and separated on a Superdex 200 Increase size exclusion column (GE Healthcare) at 0.7 ml min−1 in 20 mM Tris pH 8.0, 200 mM NaCl buffer. The ELISA protocol was adapted from a previously established immunoassay. Briefly, 96-well ELISA plates (Nunc Maxisorp) were coated overnight at 4°C with 50 μl of RBD protein at 2ug/ml in PBS (Gibco). Next day, the coating solution was removed and plates were blocked with 3% non-fat milk in PBST (PBS plus 0.1% Tween 20) for 1 hour at RT. Serum samples were inactivated (heating at 56°C for 1 hour) and diluted (1:50) in 1% non-fat milk in PBST, and added to the plates for 2 hours at RT. After three washes with 250 μl PBST in a plate washer (Biotek), the wells were incubated with anti--human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (GenScript) diluted 1:5000 for 1 hour at RT. Plates were washed thrice with PBST, 100 μl of TMB (Thermo Scientific) substrate were added in each well for 3-6 min and the reaction was stopped with 100 μl of Stop Solution (Thermo Scientific). The optical density (OD) was measured at 450 nm in a multimode plate reader (Victor Nivo, PerkinElmer). Before start of the measurements, aliquots (600 μL each) of pooled serum (Inovative Research, Inc) were frozen at -80°C. On each measurement day, 3 of these pooled serum samples were included for quality control (QC). The NMR spectrometer was calibrated daily following strict Standard Operation Procedures (SOPs) to ensure highest spectral quality and reproducibility. Every morning three different calibrations tubes were acquired to check the spectrometer was in optimal conditions. First a temperature calibration tube containing a 99.8% deuterated methanol (MeOD) standard sample in a sealed 5 mm NMR tube was used to calibrate the temperature to ensure that serum samples were run at exactly 310 K. The MeOD NMR tube was inserted into the Sample Track robot and allowed 5 min to equilibrate. After that, an automatically tune and matching was performed, locked to deuterated methanol and automatically shimmed. A standard 90°proton parameter set was used to run an experiment with 2 scans using a pulse length of 1 μs. When the experiment was processed with a line broadening of 3.0 Hz the real probe temperature was able to be calculated by measuring the distance in Hz between the two methanol peaks, The second calibration tube is a standard 2 mM sucrose sample to optimize the water suppression. Different experiments were performed evey day. For all of them the sample was locked to 90% H2O+10% D2O. The lock and shimming were done using the automated routine. The first experiment was done to optimize the offset (O1) by using a 1D NMR experiment with presaturation, a long relaxation delay and 1 scan. After that the water suppression performance is evaluated where the signal-to-noise value must be higher than 310 and (measured on the anomeric proton of sucrose), the splitting lower than 15 % and the water hump measured at 50% not bigger than 30 Hz and measured at 10% lower than 50 Hz. Using a second experiment was calculated the optimal 90° pulse for the sample. The result is optimal when half height of the TSP peak is < 0.7 Hz with no line broadening). A third tube called Quant Ref was run for quantification purposes and was based on an external reference created by an electronic device. The sample consists several standard metabolites commonly found in biofluids that are stable over the time. A 1D NOESY experiment was performed also every morning using the same parameters used for the samples and the values obtained had to be always into the same range (Dona et al., 2014) . All 1 H-NMR spectra were measured at 310 ± 0.05 K to identify different lipoprotein subfractions parameters because its success in various epidemiological studies with very large study sizes (Jiménez et al., 2018) . The NMR spectrometer was equipped with a BBI probehead with a zgradient coil and BOSS-III shim system. Four different 1 H NMR experiments were recorded per sample: a standard one-dimensional (1D) 1 H spectrum (pulseprogram: noesyphpr1d) with water presaturation, a (1D) 1 H CPMG experiment (pulseprogram: cpmgpr1d) implementing a T2 filter to suppress the broad signals of proteins and other macromolecules, a two-dimensional (2D) Jresolved experiment (pulseprogram: jresgpprqf) and, for selected samples, also a 2D 1 H TOCSY experiment (60 ms DIPSI2 mixing) to assist in metabolite identification. The list of quantified metabolites and lipoprotein subclasses was obtained automatically by B.I.QuantPS 2.0 and B.I.-LISA (Bruker BioSpin), respectively. Quantification of lipoproteins was based on the integration of their bulk-CH3 and -CH2-group signals at 0.8 and 1.25 ppm, respectively that appeared in the 1D 1 H NMR spectrum and fitting them using 105 lipoprotein and lipoprotein subclass related parameters (Jiménez et al., 2018) . The small metabolites were identified in the one-dimensional spectra using The Human Metabolome Database (HMDB) Version 4.0 and the ChenomX NMR Suite (Chenomx Inc., Edmonton, Canada). Each CPMG 1 H-NMR spectrum, after automatic processing by Topspin (Bruker Biospin, Germany), was bucketed into consecutive bins of fixed 0.03 ppm width over the region from 0.5 to 9.5 ppm, were the pertaining bin integrals (bin intensities) were obtained as average sums (i.e. by dividing the total bin integral by the number of points in the bin). The spectral region between 4.7 and 5.0 ppm (containing the residual water signal) was excluded, leaving a total of 290 bins ([9.5 -0.5 -(5.0 -4.7)] ppm / 0.03 ppm) for analysis. All bin intensities were normalized relative to the total spectrum intensity in order to minimize the effect of different concentrations. After pareto scaling, multivariate DBSCAN (Density-Based Spatial Clustering of Applications with Noise) clustering was used with bin intensities as input variables (Ester et al., 1996) . Briefly, this clustering algorithm detects groups of high density (large number of neighbors) considering a multivariate space (bins), where groups with low density or isolated samples are marked as extremes. As further input parameters for the algorithm we set eps = 10 (size of the epsilon neighborhood) and minPts = 5 (number of minimum points in the eps region), and used the dbscan R package (version 1.1-2). DBSCAN was independently applied to the two COVID and preCOVID groups, where 6 detected outliers from COVID cohort were discarded but no one forpreCOVID group. Principal Component Analysis (PCA) was used as dimensionality reduction method to facilitate a general overview over both groups (COVID and preCOVID) via the first and second principal components in score plots, while loadings provided insight into the weights of variables in each component. Separate PCA were performed for the serum metabolites and lipoprotein subclasses. In both cases, the variables were first mean-centered and then divided by their standard deviation. To assess the capacity of metabolomics data in distinguishing COVID-19, an Orthogonal Partial Least-Squares Discriminant Analysis (OPLS-DA) was performed for the full set of serum metabolites and lipoprotein subclasses, after normalizing their values. A repeated double cross validation process (rdCV) (Filzmoser et al., 2009 ) was used to select the number of orthogonal components and validate the predictive capacity. Several metrics were averaged through 100 repetitions: Area Under the Receiver Operating Characteristics (AUROC), accuracy, sensitivity and specificity. The outer loop of rdCV performed a 4-fold cross validation process. The inner loop selected the number of orthogonal components (from 1 to 5) based on AUROC in a new 7-fold cross validation process. If AUROC was not improved in at least 5% adding a new orthogonal component, then no more components were added. To measure the statistical significance of calculated metrics, a permutation test (Szymańska et al., 2012) was performed for the whole process. The number of permutations was set to 100. Then, for each permutation, new values for the metrics were obtained. The thresholds for p-values were calculated as the proportion of permuted results that reached a value at least as high as the real one (those obtained from rdCV without permuted labels). In order to visualize OPLS-DA results, a final model was built with all samples and a score plot between the predictive and the orthogonal components was generated. Loadings from OPLS-DA were used to determine those variables with a bigger contribution to the cohort separation. To quantify the metabolic effect of COVID-19, a multivariable linear model was built for each metabolite and lipoprotein subclass, using the metabolite or lipoprotein as dependent variable and the COVID-19 status (positive or control) as independent variable, adjusted by gender and age because metabolism is deeply affected by those confounding factors (Darst et al., 2019; Rist et al., 2017; Wang et al., 2020) . Coefficients and p-values associated with a COVID-19 positive variable were extracted from models. For each p-value, the 95% confidence interval was also calculated. Coefficients and intervals were normalized by their standard deviation in the control group to make them comparable between metabolites or lipoproteins. The statistical significance threshold was set to a = 0.05 and p-values were adjusted with the False Discovery Rate (FDR) method to control for Type I errors due to multiple comparisons. Individual metabolite or lipoprotein subclass analyses were summarized in forest plots, where each variable is represented by its mean value and 95% confidence interval. All analyses were performed using the R statistical software, version 3.6.0 (http://cran.rproject.org/) and the following R packages: ade4 (version 1.7-15), factoextra (1.05), ggforestplot (0.1.0), ropls (1.16.0), and tidyverse (1.3.0). Table S1 (Concentrations of metabolites and lipoproteins, Related to Figures 3 and Figure 4 ) and Table S5 (Raw spectroscopical data, Related to Transparent Methods and Figures 1-4 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Longitudinal plasma metabolomics of aging and sex Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping A Density-Based Algorithm for Discovering Clusters in Large Spatial Databases with Noise Repeated double cross validation Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by (1)H NMR Spectroscopy in a Multilaboratory Trial Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies